Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant Vaccine

NEXT STORY
Biobanks Market size worth $ 79.5 Billion, Globally, by 2028 at 5.50% CAGR: Verified Market Research®
PREV STORY
Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche’s Polivy combination reduced the risk of disease worsening or death by 27% in people with previously untreated aggressive form of lymphoma

author_avatar
NASDAQ Market News

Anthera Pharmaceuticals Announces Presentation of Blisibimod Data at the American College of Rheumatology Annual Meeting

HAYWARD, Calif., Nov. 05, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) will present additional ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals

author_avatar
NASDAQ Market News